Real-World Associations of KidneyIntelX Risk Stratification With Guideline-Directed Therapy, Kidney Outcomes, and Metabolic Trajectories in Early Diabetic Kidney Disease.
AI-guided kidney disease risk assessment helps doctors prescribe proven treatments more often, meaningfully improving outcomes for diabetic kidney disease patients.
KidneyIntelX AI-based biomarker risk stratification significantly improves guideline-directed therapy adoption and kidney outcomes in real-world T2DM-CKD patients at two centres. The study validates biomarker-guided precision nephrology as a tool to meaningfully close the treatment gap in diabetic kidney disease.
What the study was
- Study design
- Prospective real-world cohort
- Population
- T2DM patients with CKD; n=2,470; two centres
- Sample size
- 2470
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Diabetes, obesity & metabolism
Why it surfaced
Real-world multi-centre validation of biomarker-guided diabetic kidney disease care; large prospective cohort; directly practice-relevant for nephrology and diabetes.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.